[1. I. M. Verma and M. D. Weitzman, Gene therapy: twenty-first century medicine, Annu. Rev. Biochem. 74 (2005) 711-738; DOI: 10.1146/annurev.biochem.74.050304.091637.10.1146/annurev.biochem.74.050304.091637]Search in Google Scholar
[2. C. Baum, A. Schamba ch, J. Bohne and M. Galla, Retrovirus vectors: toward the plentivirus? Mol. Ther. 13 (2006) 1050-1063; DOI: 10.1016/j.ymthe.2006.03.007.10.1016/j.ymthe.2006.03.007]Search in Google Scholar
[3. C. Li, D. E. Bowles, T. van Dyke and R. J. Samulski, Adeno-associated virus vectors: potential applications for cancer gene therapy, Cancer Gene Ther. 12 (2005) 913-925; DOI: 10.1038/sj.cgt.7700876.10.1038/sj.cgt.7700876]Search in Google Scholar
[4. L. S. Young, P. F. Se arle, D. Onion and V. Mautner, Viral gene therapy strategies: from basic science to clinical application, J. Pathol. 208 (2006) 299-318; DOI: 10.1002/path.1896.10.1002/path.1896]Search in Google Scholar
[5. R. Wattiaux, N. Lauren t, S. Wa_ iaux-De Coninck and M. Jadot, Endosomes, lysosomes: their implication in gene transfer, Adv. Drug Deliv. Rev. 41 (2000) 201-208.10.1016/S0169-409X(99)00066-6]Search in Google Scholar
[6. M. S. Al-Dosari and X. Gao, Nonviral gene delivery: principle, limitations, and recent progress, AAPS J. 11 (2009) 671-681; DOI: 10.1208/s12248-009-9143-y.10.1208/s12248-009-9143-y278207719834816]Search in Google Scholar
[7. M. Morille, C. Passirani , A. Vonarbourg, A. Clavreul and J. P. Benoit, Progress in developing cationic vectors for non-viral systemic gene therapy against cancer, Biomaterials 29 (2008) 3477-3496; DOI: 10.1016/j.biomaterials.2008.04.036.10.1016/j.biomaterials.2008.04.03618499247]Search in Google Scholar
[8. Y. Kaneda and Y. Tabata, Non-viral vectors for cancer therapy, Cancer Sci. 97 (2006) 348-354; DOI: 10.1111/j.1349-7006.2006.00189.x.10.1111/j.1349-7006.2006.00189.x16630130]Search in Google Scholar
[9. J. Zabner, A. J. Fasbender , T. Moninger, K. A. Poellinger and M. J. Welsh, Cellular and molecular barriers to gene transfer by a cationic lipid, J. Biol. Chem. 270 (1995) 18997-9007.10.1074/jbc.270.32.189977642560]Search in Google Scholar
[10. I. A. Schaap, F. Eghiaian, A. des Georges and C. Veigel, Effect of envelope proteins on the mechanical properties of influenza virus, J. Biol. Chem. 287 (2012) 41078-41088; DOI: 10.1074/jbc. M112.412726.10.1074/jbc]Search in Google Scholar
[11. C. Moser, M. Muller, M. D. Kaeser, U. Weydemann and M. Amacker, Influenza virosomes as vaccine adjuvant and carrier system, Expert Rev. Vaccines 12 (2013) 779-791; DOI: 10.1586/14760584.2013.811195.10.1586/14760584.2013.811195]Search in Google Scholar
[12. D. Koppers-Lalic, M. M. Hoge nboom, J. M. Middeldorp and D. M. Pegtel, Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine, Adv. Drug Deliv. Rev. 65 (2013) 348-356; DOI: 10.1016/j.addr.2012.07.006.10.1016/j.addr.2012.07.006]Search in Google Scholar
[13. J. D. Almeida, D. C. Edwards, C. M. Brand and T. D. Heath, Formation of virosomes from influenza subunits and liposomes, Lancet 2 (1975) 899-901. 10.1016/S0140-6736(75)92130-3]Search in Google Scholar
[14. R. K. Scheule, Novel preparati on of functional Sindbis virosomes, Biochemistry 25 (1986) 4223-4232.10.1021/bi00363a009]Search in Google Scholar
[15. W. A. Petri, Jr. and R. R. Wagn er, Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis, J. Biol. Chem. 254 (1979) 4313-4316.10.1016/S0021-9258(17)30004-2]Search in Google Scholar
[16. K. Metsikko, G. van Meer and K. Simons, Reconstitution of the fusogenic activity of vesicular stomatitis virus, EMBO J. 5 (1986) 3429-3435.10.1002/j.1460-2075.1986.tb04665.x]Search in Google Scholar
[17. A. Helenius, E. Fries and J. Kart enbeck, Reconstitution of Semliki forest virus membrane, J. Cell Biol. 75 (1977) 866-880.10.1083/jcb.75.3.866]Search in Google Scholar
[18. A. Helenius, M. Sarvas and K. Simo ns, Asymmetric and symmetric membrane reconstitution by detergent elimination: Studies with Semliki-Forest-virus spike glycoprotein and penicillinase from the membrane of Bacillus licheniformis, Eur. J. Biochem. 116 (1981) 27-35.]Search in Google Scholar
[19. T. Uchida, J. Kim, M. Yamaizumi, Y. Miyake and Y. Okada, Reconstitution of lipid vesicles associated with HVJ (Sendai virus) sikes. Purification and some properties of vesicles containing nontoxic fragment A of diphtheria toxin, J. Cell Biol. 80 (1979) 10-20.10.1083/jcb.80.1.10]Search in Google Scholar
[20. S. Bagai, A. Puri, R. Blumenthal and D. P. Sarkar, Hemagglutinin-neuraminidase enhances F protein-mediated membrane fusion of reconstituted Sendai virus envelopes with cells, J. Virol. 67 (1993) 3312-3318.10.1128/jvi.67.6.3312-3318.1993]Search in Google Scholar
[21. A. Vainstein, M. Hershkovitz, S. Isra el, S. Rabin and A. Loyter, A new method for reconstitution of highly fusogenic Sendai virus envelopes, Biochim. Biophys. Acta 773 (1984) 181-188.10.1016/0005-2736(84)90081-6]Search in Google Scholar
[22. A. Jamali, M. Holtrop, A. de Haan, H. Hashemi, M. Shenagari, A. Memarnejadian, F. Roohvand, F. Sabahi, M. T. Kheiri and A. Huckriede, Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination, Immunol. Lett . 148 (2012) 77-82; DOI: 10.1016/j.imlet. 2012.08.006.]Search in Google Scholar
[23. S. G. Reed, S. Bertholet, R. N. Coler a nd M. Friede, New horizons in adjuvants for vaccine development, Trends Immunol. 30 (2009) 23-32; DOI: 10.1016/j.it.2008.09.006.10.1016/j.it.2008.09.00619059004]Search in Google Scholar
[24. J. J. Skehel and D. C. Wiley, Receptor b inding and membrane fusion in virus entry: the influenza hemagglutinin, Annu. Rev. Biochem. 69 (2000) 531-569; DOI: 10.1146/annurev.biochem.69.1.531.10.1146/annurev.biochem.69.1.53110966468]Search in Google Scholar
[25. M. Ohuchi, N. Asaoka, T. Sakai and R. Ohu chi, Roles of neuraminidase in the initial stage of influenza virus infection, Microbes Infect. 8 (2006) 1287-1293; DOI: 10.1016/j.micinf.2005.12.008.10.1016/j.micinf.2005.12.00816682242]Search in Google Scholar
[26. R. Wagner, M. Matrosovich and H. D. Klenk , Functional balance between haemagglutinin and neuraminidase in influenza virus infections, Rev. Med. Virol. 12 (2002) 159-166; DOI: 10.1002/ rmv.352.10.1002/rmv.35211987141]Search in Google Scholar
[27. T. Nakajima, Novel gene transfer systems: i ntelligent gene transfer vectors for gene medicines, Curr. Top. Med. Chem. 12 (2012) 1594-1602.]Search in Google Scholar
[28. T. Stegmann, H. W. Morselt, F. P. Booy, J. F . van Breemen, G. Scherphof and J. Wilschut, Functional reconstitution of influenza virus envelopes, EMBO J. 6 (1987) 2651-2659.10.1002/j.1460-2075.1987.tb02556.x]Search in Google Scholar
[29. M. G. Cusi, Applications of influenza virosom es as a delivery system, Hum. Vaccin. 2 (2006) 1-7.10.4161/hv.2.1.249417012895]Search in Google Scholar
[30. E. Soussan, S. Cassel, M. Blanzat and I. Rico- La_ es, Drug delivery by so_ ma_ er: matrix and vesicular carriers, Angew. Chem. Int. Ed. Engl. 48 (2009) 274-288; DOI: 10.1002/anie.200802453.10.1002/anie.20080245319072808]Search in Google Scholar
[31. G. V. Radha, T. S. Rani and B. Sarvani, A revie w on proniosomal drug delivery system for targeted drug action, J. Basic Clin. Pharm. 4 (2013) 42-48; DOI: 10.4103/0976-0105.113609.10.4103/0976-0105.113609397926324808669]Search in Google Scholar
[32. H. I. Chang and M. K. Yeh, Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy, Int. J. Nanomedicine 7 (2012) 49-60; DOI: 10.2147/IJ N.S26766.]Search in Google Scholar
[33. A. K. Dey and I. K. Srivastava, Novel adjuvants a nd delivery systems for enhancing immune responses induced by immunogens, Expert Rev. Vaccines 10 (2011) 227-251; DOI: 10.1586/erv.10.142.10.1586/erv.10.14221105782]Search in Google Scholar
[34. M. L. De Temmerman, J. Rejman, J. Demeester, D. J. Irvine, B. Gander and S. C. De Smedt, Particulate vaccines: on the quest for optimal delivery and immune response, Drug Discov. Today 16 (2011) 569-582; DOI: 10.1016/j.drudis.2011.04.006. 10.1016/j.drudis.2011.04.00621570475]Search in Google Scholar
[35. A. Huckriede, L. Bungener, T. Stegmann, T. Daemen, J. Medema, A. M. Palache and J. Wilschut, The virosome concept for influenza vaccines, Vaccine 23 (Suppl. 1) (2005) S26-S38; DOI: 10.1016/j. vaccine.2005.04.026.]Search in Google Scholar
[36. A. M. Harandi and D. Medaglini, Mucosal adjuvants, C urr. HIV Res. 8 (2010) 330-335.10.2174/157016210791208695]Search in Google Scholar
[37. I. Jabbal-Gill, Nasal vaccine innovation, J. Drug Tar get. 18 (2010) 771-786; DOI: 10.3109/ 1061186X.2010.523790.10.3109/1061186X.2010.523790]Search in Google Scholar
[38. S. Beg, A. Samad, I. Nazish, R. Sultana, M. Rahman, M. Z. Ahmad and M. Akbar, Colloidal drug delivery systems in vaccine delivery, Curr. Drug Targets 14 (2013) 123-137.10.2174/138945013804806523]Search in Google Scholar
[39. S. M. Moghimi and J. Szebeni, Stealth liposomes and lon g circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties, Prog. Lipid Res. 42 (2003) 463-478.]Search in Google Scholar
[40. E. Waelti, N. Wegmann, R. Schwaninger, A. Wetterwald, C. Wingenfeld, B. Rothen-Rutishauser and C. D. Gimmi, Targeting her-2/neu with antirat Neu virosomes for cancer therapy, Cancer Res. 62 (2002) 437-444.]Search in Google Scholar
[41. E. Mastrobattista, P. Schoen, J. Wilschut, D. J. Crommeli n and G. Storm, Targeting influenza virosomes to ovarian carcinoma cells, FEBS Lett. 509 (2001) 71-76.10.1016/S0014-5793(01)03112-X]Search in Google Scholar
[42. J. Liu, J. Wu, B. Wang, S. Zeng, F. Qi, C. Lu, Y. Kimura a nd B. Liu, Oral vaccination with a liposomeencapsulated influenza DNA vaccine protects mice against respiratory challenge infection, J. Med. Virol. 86 (2014) 886-894; DOI: 10.1002/jmv.23768.10.1002/jmv.23768]Search in Google Scholar
[43. J. de Jonge, J. M. Leenhouts, M. Holtrop, P. Schoen, P. Sch errer, P. R. Cullis, J. Wilschut and A. Huckriede, Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA, Biochem. J. 405 (2007) 41-49; DOI: 10.1042/BJ20061756.10.1042/BJ20061756]Search in Google Scholar
[44. J. de Jonge, M. Holtrop, J. Wilschut and A. Huckriede, Recon stituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs, Gene Ther. 13 (2006) 400-411; DOI: 10.1038/sj.gt.3302673.10.1038/sj.gt.3302673]Search in Google Scholar
[45. L. Bungener, K. Serre, L. Bij l, L. Leserman, J. Wilschut, T. Daemen and P. Machy, Virosome-mediated delivery of protein antigens to dendritic cells, Vaccine 20 (2002) 2287-2295.10.1016/S0264-410X(02)00103-2]Search in Google Scholar
[46. P. Schoen, A. Chonn, P. R. Cullis, J. Wilschut and P. Scherrer , Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles, Gene Ther. 6 (1999) 823-832; DOI: 10.1038/sj.gt.3300919.10.1038/sj.gt.330091910505107]Search in Google Scholar
[47. R. Bron, A. Ortiz and J. Wilschut, Cellular cytoplasmic delive ry of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes), Biochemistry 33 (1994) 9110-9117.10.1021/bi00197a0138049214]Search in Google Scholar
[48. L. Bungener, A. Huckriede, A. de Mare, J. de Vries-Idema, J. Wil schut and T. Daemen, Virosomemediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity, Vaccine 23 (2005) 1232-1241; DOI: 10.1016/j.vaccine.2004.09.002.10.1016/j.vaccine.2004.09.002]Search in Google Scholar
[49. A. Arkema, A. Huckriede, P. Schoen, J. Wilschut and T. Daemen, In duction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes, Vaccine 18 (2000) 1327-1333.10.1016/S0264-410X(99)00404-1]Search in Google Scholar
[50. Y. Kaneda, Virosomes: evolution of the liposome as a targeted drug delivery system, Adv. Drug Deliv. Rev. 43 (2000) 197-205.]Search in Google Scholar
[51. N. Nakamura, D. A. Hart, C. B. Frank, L. L. Marchuk, N. G. Shrive, N. Ota, K. Taira, H. Yoshikawa and Y. Kaneda, Efficient transfer of intact oligonucleotides into the nucleus of ligament scar fibroblasts by HVJ-cationic liposomes is correlated with effective antisense gene inhibition, J. Biochem. 129 (2001) 755-759.10.1093/oxfordjournals.jbchem.a00291611328598]Search in Google Scholar
[52. Y. Krishnamachari, S. M. Geary, C. D. Lemke, and A. K. Salem, Nanopa rticle delivery systems in cancer vaccines, Pharm. Res. 28 (2011) 215-236; DOI: 10.1007/s11095-010-0241-4.10.1007/s11095-010-0241-4355924320721603]Search in Google Scholar
[53. T. Stegmann, T. Kamphuis, T. Meij erhof, E. Goud, A. de Haan and J. Wi lschut, Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation, Vaccine 28 (2010) 5543-5550; DOI: 10.1016/j.vaccine.2010.06.041. 10.1016/j.vaccine.2010.06.04120600502]Search in Google Scholar
[54. M. Shafique, J. Wilschut and A. de Haan, Induction of mucosal and syst emic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands, Vaccine 30 (2012) 597-606; DOI: 10.1016/j.vaccine.2011.11.054.10.1016/j.vaccine.2011.11.05422120195]Search in Google Scholar
[55. R. J. Cox, G. Pedersen, A. S. Madhun, S. Svindland, M. Saevik, L. Break well, K. Hoschler, M. Willemsen, L. Campitelli, J. K. Nostbakken, G. J. Weverling, J. Klap, K. C. McCullough, M. Zambon, R. Kompier and H. Sjursen, Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial, Vaccine 29 (2011) 8049-8059; DOI: 10.1016/j.vaccine.2011.08.042.10.1016/j.vaccine.2011.08.04221864624]Search in Google Scholar
[56. M. D. Joshi, W. J. Unger, G. Storm, Y. van Kooyk and E. Mastrobattista, Targeting tumor antigens to dendritic cells using particulate carriers, J. Control. Release 161 (2012) 25-37; DOI: 10.1016/j.jconrel. 2012.05.010.]Search in Google Scholar
[57. D. Felnerova, J. F. Viret, R. Gluck and C. Moser, Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs, Curr. Opin. Biotech. 15 (2004) 518-529; DOI: 10.1016/j.copbio. 2004.10.005.]Search in Google Scholar
[58. G. Leroux-Roels, Unmet needs in modern vaccinology: adjuvants to improve t he immune response, Vaccine 28 (Suppl. 3) (2010) C25-C36; DOI: 10.1016/j.vaccine.2010.07.021.10.1016/j.vaccine.2010.07.02120713254]Search in Google Scholar
[59. P. Nordly, H. B. Madsen, H. M. Nielsen and C. Foged, Status and future pros pects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators, Expert Opin. Drug Deliv. 6 (2009) 657-672; DOI: 10.1517/17425240903018863.10.1517/1742524090301886319538037]Search in Google Scholar
[60. P. G. Cech, T. Aebi, M. S. Abdallah, M. Mpina, E. B. Machunda, N. Westerfeld , S. A. Stoffel, R. Zurbriggen, G. Pluschke, M. Tanner, C. Daubenberger, B. Genton and S. Abdulla, Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: Randomized phase 1b trial in semi-immune adults & children, PLoS One 6 (2011) e22273; DOI: 10.1371/journal. pone.0022273.]Search in Google Scholar
[61. A. Cassone and A. Casadevall, Recent progress in vaccines against fungal dis eases, Curr. Opin. Microbiol. 15 (2012) 427-433; DOI: 10.1016/j.mib.2012.04.004.10.1016/j.mib.2012.04.004342435222564747]Search in Google Scholar
[62. J. Torresi, D. Johnson and H. Wedemeyer, Progress in the development of prev entive and therapeutic vaccines for hepatitis C virus, J. Hepatol. 54 (2011) 1273-1285; DOI: 10.1016/j.jhep.2010.09.040.10.1016/j.jhep.2010.09.04021236312]Search in Google Scholar
[63. I. Naldi, M. Taranta, L. Gherardini, G. Pelosi, F. Viglione, S. Grimaldi, L. P ani and C. Cinti, Novel epigenetic target therapy for prostate cancer: a preclinical study, PLoS One 9 (2014) e98101; DOI: 10.1371/journal.pone.0098101.10.1371/journal.pone.0098101403113724851905]Search in Google Scholar
[64. R. M. Roy and B. S. Klein, Dendritic cells in antifungal immunity and vaccine design, Cell Host Microbe 11 (2012) 436-446; DOI: 10.1016/j.chom.2012.04.005.10.1016/j.chom.2012.04.005340196522607797]Search in Google Scholar
[65. A. Huckriede, L. Bungener, W. ter Veer, M. Holtrop, T. Daemen, A. M. Palache and J. Wilschut, Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity, Vaccine 21 (2003) 925-931.]Search in Google Scholar
[66. E. Nardin, The past decade in malaria synthetic peptide vaccine clinical trials, Hum. Vaccin. 6 (2010) 27-38.10.4161/hv.6.1.960120173408]Search in Google Scholar
[67. J. Wilschut, Influenza vaccines: the virosome concept, Immunol. Lett. 122 (2009) 118-121; DOI: 10.1016/j.imlet.2008.11.006.10.1016/j.imlet.2008.11.00619100779]Search in Google Scholar
[68. C. Hatz, R. van der Ploeg, B. R. Beck, G. Frosner, M. Hunt and C. Herzog, Successf ul memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years, Clin. Vaccine Immunol. 18 (2011) 885-887; DOI: 10.1128/CVI.00358-10.10.1128/CVI.00358-10312252821411599]Search in Google Scholar
[69. W. Z. Zhou, D. S. Hoon, S. K. Huang, S. Fujii, K. Hashimoto, R. Morishita, and Y. K aneda, RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization, Hum. Gene Ther. 10 (1999) 2719-2724; DOI: 10.1089/10430349950016762.10.1089/1043034995001676210566900]Search in Google Scholar
[70. M. G. Cusi, M. T. Del Vecchio, C. Terrosi, G. G. Savellini, G. Di Genova, M. La Plac a, F. Fallarino, C. Moser, C. Cardone, G. Giorgi, G. Francini and P. Correale, Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine, J. Immunol. 174 (2005) 7210-7216. 10.4049/jimmunol.174.11.721015905566]Search in Google Scholar
[71. P. Correale, M. T. Del Vecchio, T. Renieri, G. Di Genova, M. La Placa, C. Remondo, G. G. Savellini, C. Terrosi, R. Zurbriggen, M. Amacker, G. Francini and M. G. Cusi, Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine, Cancer Lett. 263 (2008) 291-301; DOI: 10.1016/j.canlet.2008.01.018.10.1016/j.canlet.2008.01.01818291576]Search in Google Scholar
[72. U. Wiedermann, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer, R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner and C. C. Zielinski, A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study, Breast Cancer Res. Treat. 119 (2010) 673-683.10.1007/s10549-009-0666-920092022]Search in Google Scholar
[73. R. Schwaninger, E. Waelti, P. Zajac, A. Wetterwald, D. Mueller and C. D. Gimmi, Virosom es as new carrier system for cancer vaccines, Cancer Immunol. Immunother. 53 (2004) 1005-17; DOI: 10.1007/ s00262-004-0545-5.10.1007/s00262-004-0545-515185010]Search in Google Scholar
[74. L. Bungener, A. de Mare, J. de Vries-Idema, P. Sehr, A. van der Zee, J. Wilschut and T. Daemen, A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease, Antivir. Ther. 11 (2006) 717-727.10.1177/135965350601100616]Search in Google Scholar
[75. M. Walczak, A. de Mare, A. Riezebos-Brilman, J. Regts, B. N. Hoogeboom, J. T. Visser, M. Fiedler, P. Jansen-Durr, A. G. van der Zee, H. W. Nij man, J. Wilschut and T. Daemen, Heterologous primeboost immunizations with a virosomal and an alphavirus replicon vaccine, Mol. Pharm. 8 (2011) 65-77; DOI: 10.1021/mp1002043.10.1021/mp100204320825215]Search in Google Scholar
[76. M. Adamina, R. Schumacher, P. Zajac, W. P. Weber, R. Rosenthal, C. Groeper, C. Feder, R. Z urbriggen, M. Amacker, G. C. Spagnoli, D. Oertli and M. Heberer, Advanced liposomal vectors as cancer vaccines in melanoma immunotherapy, J. Liposome Res. 16 (2006) 195-204; DOI: 10.1080/ 08982100600848546.10.1080/0898210060084854616952874]Search in Google Scholar
[77. R. Schumacher, M. Amacker, D. Neuhaus, R. Rosenthal, C. Groeper, M. Heberer, G. C. Spagnoli , R. Zurbriggen and M. Adamina, Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro, Vaccine 23 (2005) 5572-5582; DOI: 10.1016/j.vaccine.2005.07.099.10.1016/j.vaccine.2005.07.09916165256]Search in Google Scholar
[78. M. K. Zakaria, I. Khan, P. Mani, P. Chattopadhyay, D. P. Sarkar and S. Sinha, Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells, BMC Cancer 14 (2014) 582; DOI: 10.1186/1471-2407-14-582.10.1186/1471-2407-14-582415391125108398]Search in Google Scholar
[79. Y. Nishimura, H. Mieda, J. Ishii, C. Ogino, T. Fujiwara and A. Kondo, Targeting cancer cell- specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes, J. Nanobiotechnol. 11 (2013) 19; DOI: 10.1186/1477-3155-11-19.10.1186/1477-3155-11-19369938023800313]Search in Google Scholar
[80. C. Cinti, M. Taranta, I. Naldi and S. Grimaldi, Newly engineered magnetic erythrocytes for s ustained and targeted delivery of anti-cancer therapeutic compounds, PLoS One 6 (2011) e17132; DOI: 10.1371/journal.pone.0017132.10.1371/journal.pone.0017132304415421373641]Search in Google Scholar
[81. M. Kurooka and Y. Kaneda, Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells, Cancer Res. 67 (2007) 227-236; DOI: 10.1158/ 0008-5472.CAN-06-1615.10.1158/0008-5472.CAN-06-161517210703]Search in Google Scholar
[82. A. Fujihara, M. Kurooka, T. Miki and Y. Kaneda, Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation, Cancer Immunol. Immunother. 57 (2008) 73-84; DOI: 10.1007/s00262-007-0351-y.10.1007/s00262-007-0351-y17602226]Search in Google Scholar
[83. M. Tanaka, T. Shimbo, Y. Kikuchi, M. Matsuda and Y. Kaneda, Sterile alpha motif containing dom ain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon, Int. J. Cancer. 126 (2010) 1982-1991; DOI: 10.1002/ij c.24965.10.1002/ijc.2496519830690]Search in Google Scholar
[84. Y. Kawaguchi, Y. Miyamoto, T. Inoue and Y. Kaneda, Efficient eradication of hormone-resistant h uman prostate cancers by inactivated Sendai virus particle, Int. J. Cancer 124 (2009) 2478-2487; DOI: 10.1002/ij c.24234.10.1002/ijc.2423419173282]Search in Google Scholar